A new hope: Trikafta for the treatment of cystic fibrosis

As one of the most common autosomal recessive conditions in Ireland, cystic fibrosis (CF) is of keen interest to healthcare professionals. Throughout its long history, the treatment strategies for this condition have focused on mitigating the effects described by patients: the thick secretions; the constant infections; and, the inability to absorb nutrients. With the advent of modulator therapies, the focus has now shifted to correcting the underlying genetic defect. Trikafta is the most recent of these therapies and has been shown to have the greatest effects on both objective and subjective measures of disease control compared to other therapies. This review article will focus on the background behind Trikafta, its method of action, and its effects on both disease progression and patient well-being. This drug has the potential to change the way we treat and perceive this ancient disease.